Basolli Gomiero Mirella sold $148K of AFYA

Basolli Gomiero Mirella (Vice President) sold 10,000 shares of Afya Ltd (AFYA) at $14.80 ($0.15M total) on 2026-06-26.

Original reporting
SEC EDGAR · Basolli Gomiero Mirella
Published Jun 30, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AFYA
Neutral
medium confidence
Mentioned
$AFYA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AFYANeutralLow
01

Why it matters

The newest fact is the reported open-market sale of 10,000 shares by an officer at $14.80, with post-sale holdings of 34,530 shares.

02

Market read

This is a routine insider-sale datapoint; it can marginally influence sentiment but does not change fundamentals based on the provided text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, the signal is weak.

Relevance 4/10Novelty 5/10Timing: filed 2026-06-30 (covers sale dated 2026-06-26)

Background

The article is a SEC Form 4 insider transaction disclosure for Afya Ltd (AFYA).

Company-level read

Ticker impact

$AFYANeutralMedium confidence
Context

Afya Ltd VP Basolli Gomiero Mirella sold 10,000 shares at $14.80 in a Form 4 open-market sale, reducing holdings to 34,530.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is a single officer open-market sale with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, deals, or regulatory actions).

Market effects

No sector read-across; this is an isolated insider transaction with no disclosed business development.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan, some traders may interpret it as a stronger signal than typical scheduled selling—though the article provides no reason for the sale.

Key entities

  • Afya Ltd

    Subject of the Form 4 insider transaction disclosure.

  • Basolli Gomiero Mirella

    Vice President who sold 10,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AFYAMed

Afya Limited (AFYA) Q3 Revenue Rises 6.1% to R$985.2M

Afya Limited reported Q3 2026 revenue of R$985.2M, up 6.1% YoY, and Adjusted EBITDA of R$433.8M, up 8.7%. Nine-month net income rose 6.9% to R$634.0M. The company reaffirmed its full-year 2026 guidance. The next catalysts are shareholder and regulatory decisions on its proposed merger with Yduqs.

$AFYAHigh

Afya Ltd (AFYA): Financial results for Q3 2026

Afya Ltd (AFYA) furnished an SEC Form 6-K — earnings release. Afya Limited Announces Third Quarter and Nine Months 2026 Financial Results Strong Cash Conversion and Continued Earnings Growth Full-Year 2026 Guidance Reaffirmed Belo Horizonte, Brazil, November 12, 2026 – Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the l

$AFYAHigh

BofA upgrades Afya stock rating on exam rule changes

BofA upgraded Afya (AFYA) to Buy, lowering its price target to $16. The firm cited Afya's resilient student base, low leverage, and recent exam rule changes as reasons. Afya trades at $10.24, near its 52-week low, with a 6.32 P/E ratio and 30% free cash flow yield. Afya reported 6% Q2 and 7% H1 revenue growth, with net income rising 14% and 7% respectively. JPMorgan also upgraded Afya to Overweight, expecting merger synergies.